今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

苹果用户更钟情Apple Music，订阅率领先Spotify？

市场分析公司CIRP最新发布的报告显示，在美国苹果用户中，Apple Music的订阅率已经达到40%，相比之下，Spotify则为29%。 这意味着，在苹果设备用户群体中，Apple Music已经成为最受欢迎的音乐流媒体服务。

报告显示，尽管Spotify在美国拥有4400万付费用户，仍然领先于Apple Music的3200万用户，但从用户增长趋势来看，Apple Music正在快速追赶。2020年，Apple Music在美国的订阅率仅为34%，而Spotify则为31%。在短短三年时间里，Apple Music已经将用户占比提升了6个百分点，而Spotify只增长了2个百分点。

Apple Music为何能够在美国市场快速增长？ 分析人士认为，这主要得益于以下几个因素：

• 与苹果设备的深度整合： Apple Music是苹果生态系统的一部分，可以直接在iPhone、iPad和Mac等设备上使用。用户可以直接在音乐应用中订阅Apple Music，并在所有设备上享受无缝的音乐体验。相比之下，Spotify需要用户下载单独的应用，并且在不同设备之间的切换体验可能不如Apple Music流畅。
• 丰富的音乐内容： Apple Music拥有超过9000万首歌曲，涵盖了各种流派和风格。此外，Apple Music还拥有独家内容，例如来自泰勒·斯威夫特、碧昂斯等知名歌手的专辑。
• 诱人的家庭套餐： Apple Music提供家庭套餐，最多可供6名家庭成员共享。这对于拥有多个成员的家庭来说更具性价比。

尽管Apple Music在美国市场取得了领先地位，但Spotify在全球范围内仍然是最大的音乐流媒体服务。 据Statista估计，截至2024年6月，Spotify的全球付费用户数已达到4.33亿，而Apple Music为3.6亿。

未来，两大音乐流媒体平台之间的竞争将更加激烈。Spotify可能会推出更多针对美国市场的优惠政策，而Apple Music则可能继续加强与苹果生态系统的整合，并推出更多独家内容。